MedTrace Logo

A Clinical Trial to Evaluate the Efficacy and Safety of MXP22 on Liver Health

NCT05808049 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-09-06

No results posted yet for this study

Summary

A randomized, double blind, placebo controlled clinical trial to evaluate the efficacy and safety of MXP22 on liver health

Conditions

  • Non-Alcoholic Fatty Liver Disease

Interventions

OTHER

MXP22 (Probiotic and antioxidant capsule)

Dose: NLT 4 Billion CFU/Capsule Route: Oral Administration Regimen: 1 capsule to be taken once daily after lunch for 120 days

OTHER

Placebo (Microcrystalline Cellulose)

Dose: NLT 4 Billion CFU/Capsule Route: Oral Administration Regimen: 1 capsule to be taken once daily after lunch for 120 days

Sponsors & Collaborators

  • Vedic Lifesciences Pvt. Ltd.

    lead INDUSTRY

Principal Investigators

  • Dr. Sudhir Maharshi, MBBS DNB Gastro · Dr. Sudhir Maharshi Gastro clinic

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-06
Primary Completion
2023-07-04
Completion
2023-07-04

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05808049 on ClinicalTrials.gov